Agreements

Date: 2017-04-11

Type of information: Commercialisation agreement

Compound: Xadago™ (safinamide)

Company: Zambon (Italy) Valeo Pharma (Canada)

Therapeutic area: Neurodegenerative diseases

Type agreement: commercialisation

Action mechanism: Monoamine oxidase inhibitor. Safinamide has a novel dual mechanism of action based on the enhancement of the dopaminergic function (through potent reversible inhibition of MAO-B and of dopamine uptake) and inhibition of excessive release of glutamate.

Disease: add-on therapy to a stable dose of a single dopamine agonist in early Parkinson’s disease patients add-on therapy to levodopa alone or in combination with other Parkinson’s disease treatments in mid-to late stage Parkinson’s disease patients

Details:

• • On April 11, 2017, Newron Pharmaceuticals announced that its partner Zambon has granded Valeo Pharma exclusive rights to commercialise for the Canadian market to Xadago® (safinamide), licensed from Newron Pharmaceuticals. Under the terms of the agreement, Valeo Pharma will be responsible for all regulatory, sales and marketing, quality, and distribution activities in Canada.

Financial terms:

• Valeo Pharma will pay Zambon upfront, regulatory and commercial milestone payments as well as royalties on product sales.

Latest news:

Is general: Yes